ELSEVIER

Toxicology 113 (1996) 369–372

TOXICOLOGY

Volume contents

Volume 113 (1996)

Special Issue

EVALUATION OF BUTADIENE AND ISOPRENE HEALTH RISKS

Proceedings of the International Symposium held in Blaine, Washington on June 27–29, 1995

Foreword xiii

Introduction

International symposium on the evaluation of health risks of butadiene and isoprene: general introduction
M.G. Bird (USA) 2–4
Risk assessment for butadiene: Introductory and summary comments
G.S. Omenn (USA) 5–11

Session 1. METABOLISM AND PHARMACOKINETICS
Chair: L.S. Birnbaum (NHEERL-US EPA)
Co-Chair: D.A. Keller (E.I. du Pont de Nemours and Company)

Metabolism and pharmacokinetics of 1,3-butadiene
L.S. Birnbaum, D.A. Keller (USA) 14–16
Metabolism of 1,3-butadiene: species differences
R.F. Henderson, J.R. Thornton-Manning, W.E.Bechtold, A.R. Dahl (USA) 17–22
Biochemistry of 1,3-butadiene metabolism and its relevance to 1,3-butadiene-induced carcinogenicity
A.A. Elfarra, R.J. Krause, R.R. Selzer (USA) 23–30
Effects of the structure of a toxicokinetic model of butadiene inhalation exposure on computed production of carcinogenic intermediates
M.C. Kohn, R.L. Melnick (USA) 31–39
PBPK model for butadiene metabolism to epoxides: quantitative species differences in metabolism
G. Johanson, J.G. Filser (Sweden, Germany) 40–47
Metabolism of butadiene by mice, rats, and humans: a comparison of physiologically based toxicokinetic model predictions and experimental data
J.A. Bond, M.W. Himmelstein, M. Seaton, P. Boogaard, M.A. Medinsky (USA) 48–54

Session 2. BIOLOGICAL EFFECTS
Chair: R.J. Albertini (The University of Vermont)
Co-Chair: G.C. Becking (WHO, International Programme on Chemical Safety)

Noncancer endpoints associated with butadiene exposure: biomarkers, genotoxicity and reproductive toxicity
R.J. Albertini, G. Becking (USA) 56–58
Murine thymic lymphoma is associated with a species-specific hematopoietic progenitor cell subpopulation
R.D. Irons, D.B. Colagiovanni, W.S. Stillman (USA) 59–67

2a. Genotoxicity and Biomarkers

Macromolecular adducts of butadiene
N.Y. Tretyakova, Y.-p. Lin, P.B. Upton, R. Sangaiah, J.A. Swenberg (USA) 70–76
Assessment of exposure to butadiene in the process industry
M. Sorsa, S. Osterman-Golkar, K. Peltonen, S.T. Saarikoski, R. Šram (Finland, Sweden, Czech Republic) 77–83
Biological monitoring for mutagenic effects of occupational exposure to butadiene
J.B. Ward Jr., M.M. Ammenheuser, E.B. Whorton Jr., W.E. Bechtold, K.T. Kelsey, M.S. Legator (USA) 84–90
Biological effect monitoring in industrial workers from the Czech Republic exposed to low levels of butadiene
A.D. Tates, F.J. van Dam, F.A. de Zwart, F. Darroudi, A.T. Natarajan, P. Rössner, K. Peterková, K. Peltonen, N.A. Demopoulos, G. Stephanou, D. Vlachodimitropoulos, R. J. Srám (The Netherlands, Czech Republic, Finland, Greece) 91–99
hprt Mutation frequency among workers exposed to 1,3-butadiene in China
R.B. Hayes, L. Xi, W.E. Bechtold, N. Rothman, M. Yao, R. Henderson, L. Zhang, M.T. Smith, D. Zhang, J. Wiemels, M. Dosemeci, S. Yin, J.P. O'Neill (USA, China) 100–105
Mutagenicity and mutational spectra of 1,3-butadiene in the bone marrow of B6C3F1 *lacI* transgenic mice
L. Recio, S. Sisk, K. Meyer, L. Pluta, J.A. Bond (USA) 106–111
Biological monitoring of butadiene exposure by measurement of haemoglobin adducts
K.A. Richardson, H.J.J.J. Megens, J.D. Webb, N.J. van Sittert (The Netherlands, UK) 112–118

2b. Reproductive and Developmental Toxicity

Male-mediated F_1 effects in mice exposed to 1,3-butadiene
D. Anderson, A.J. Edwards, M.H. Brinkworth, J.A. Hughes (UK) 120–127
Species difference in the ovarian toxicity of 1,3-butadiene epoxides in B6C3F_1 mice and Sprague-Dawley rats
J.K. Doerr, E.A. Hollis, I.G. Sipes (USA) 128–136
Review of reproductive and developmental toxicity of 1,3-butadiene
M.S. Christian (USA) 137–143

Session 3. EPIDEMIOLOGY
Chair: P. Cole (University of Alabama, School of Public Health)
Co-Chair: S.R. Cowles (Amoco Corporation)

Introduction to epidemiology session papers
S.R. Cowles (USA) 146–147
Butadiene epidemiology: a summary of results and outstanding issues
J.F. Acquavella (USA) 148–156
Mortality study of workers employed in 1,3-butadiene production units identified from a large chemical workers cohort
E.M. Ward, J.M. Fajen, A.M. Ruder, R.A. Rinsky, W.E. Halperin, C.A. Fessler-Flesch (USA) 157–168
Mortality update of butadiene production workers
B.J. Divine, C.M. Hartman (USA) 169–181
A follow-up study of synthetic rubber workers
E. Delzell, N. Sathiakumar, M. Hovinga, M. Macaluso, J. Julian, R. Larson, P. Cole, D.C.F. Muir (USA, Canada) 182–189
Leukemia and cumulative exposure to butadiene, styrene and benzene among workers in the synthetic rubber industry
M. Macaluso, R. Larson, E. Delzell, N. Sathiakumar, M. Hovinga, J. Julian, D. Muir, P. Cole (USA, Canada) 190–202
Future research needs for non-cancer and cancer effects among populations exposed to 1,3-butadiene
A.M. Koppikar (USA) 203–209

Session 4. RISK ASSESSMENT
Chair: D.J. Paustenbach (McLaren Hart-ChemRisk)
Co-chair: R.O. McClellan (CIIT)

Conducting a state-of-the-art risk assessment of 1,3-butadiene
D.J. Paustenbach (USA) 212–214
Review of risk assessments on 1,3-butadiene (1985–1991)
S.Z. Cagen, R.L.M. Macdonald, G.V. Gelder (USA) 215–220

Risk assessment of butadiene in ambient air; the approach used in the UK
R.J. Fielder (UK) 221–225
Risk assessment of butadiene for the Existing Substances Regulation (ESR) in the European Union
I.M. Brooke (UK) 226–230
Using PBPK modeling and comprehensive realism methodology for the quantitative cancer risk assessment of butadiene
R.L. Sielken Jr., R.H. Reitz, S.M. Hays (USA) 231–237

Session 5. ISOPRENE TOXICOLOGY
Chair: J.S. Bus (The Dow Chemical Company)
Co-chair: P.G. Gervasi (CNR)

Isoprene toxicology: introduction and overview
J.S. Bus (USA) 240–241
Isoprene: background and issues
R.D.F.M. Taalman (The Netherlands) 242–246
Inhalation toxicity and carcinogenicity of isoprene in rats and mice: comparisons with 1,3-butadiene
R.L. Melnick, R.C. Sills, J.H. Roycroft, B.J. Chou, H.A. Ragan, R.A. Miller (USA) 247–252
Chronic inhalation oncogenicity study of isoprene in B6C3F$_1$ mice
M.E. Placke, L. Griffis, M. Bird, J. Bus, R.L. Persing, L.A. Cox, Jr. (USA) 253–262
Isoprene cancer risk and the time pattern of dose administration
L.A. Cox, Jr., M.G. Bird, L. Griffis (USA) 263–272
Metabolism of isoprene in vivo
A.R. Dahl (USA) 273–277
Toxicokinetics of isoprene in rodents and humans
J.G. Filser, G.A. Csanády, B. Denk, M. Hartmann, A. Kauffmann, W. Kessler, P.E. Kreuzer, C. Pütz, J.H. Shen, P. Stei (Germany) 278–287

Session 6. POSTERS
Chair: J.R. Thornton-Manning (ITRI)
Co-Chair: M.W. Himmelstein (E.I. du Pont de Nemours and Company)

6a. Metabolism and Pharmacokinetics

Studies on the molecular toxicology of buta-1,3-diene and isoprene epoxides
C. Bleasdale, R.D. Small, W.P. Watson, J. Wilson, B.T. Golding (UK, The Netherlands) 290–293
Differential reactivities of the mono- and di-epoxide of 1,3-butadiene
H.M. Bolt, M. Capellmann, B. Jelitto, U. Hindermeier, L.I. Kirkovsky (Germany) 294–296
Hepatic and pulmonary glutathione conjugation of 1,2:3,4-diepoxybutane in human, rat, and mouse in vitro
P.J. Boogaard, S.C-J. Sumner, M.J. Turner, J.A. Bond (USA, The Netherlands) 297–299
A physiological toxicokinetic model for 1,3-butadiene in rodents and man: blood concentrations of 1,3-butadiene, its metabolically formed epoxides, and of haemoglobin adducts — relevance of glutathione depletion
G.A. Csanády, P.E. Kreuzer, C. Baur, J.G. Filser (Germany) 300–305
Metabolism of 1,3-butadiene: inhalation pharmacokinetics and tissue dosimetry of butadiene epoxides in rats and mice
M.W. Himmelstein, M.J. Turner, B. Asgharian, J.A. Bond (USA) 306–309
Pharmacokinetic model describing the disposition of butadiene and styrene in mice
T.L. Leavens, J.A. Bond (USA) 310–313
1,3-Butadiene metabolism by lung airways isolated from mice and rats
M.J. Seaton, C.G. Plopper, J.A. Bond (USA) 314–317
Physiologically based pharmacokinetic modeling of blood and tissue epoxide measurements for butadiene
L.M. Sweeney, M.W. Himmelstein, P.M. Schlosser, M.A. Medinsky (USA) 318–321
Gender and species differences in the metabolism of 1,3-butadiene to butadiene monoepoxide and butadiene diepoxide in rodents following low-level inhalation exposures
J.R. Thornton-Manning, A.R. Dahl, W.E. Bechtold, R.F. Henderson (USA) 322–325

6b. Genotoxicity and Biomarkers

Biological formation of the 1,3-butadiene DNA adducts 7-*N*-(2-hydroxy-3-buten-1-yl)guanine, 7-*N*-(1-hydroxy-3-buten-2-yl)guanine and 7-*N*-(2,3,4-trihydroxy-butyl)guanine
H.M. Bolt, B. Jelitto (Germany) 328–330

Liquid chromatography/electrospray ionization tandem mass spectroscopy (LC/ESI MS/MS) analysis of 1,2-epoxybutene adducts of purine deoxynucleosides
S.J. Kambouris, A.K. Chaudhary, I.A. Blair (USA) 331–335
Cytogenetic effects of butadiene metabolites in rat and mouse splenocytes following in vitro exposures
A.D. Kligerman, C.L. Doerr, V.S. Milholland, A.H. Tennant (USA) 336–340
^{32}P-postlabeling of 1,3-butadiene and 4-vinyl-1-cyclohexene metabolite-DNA adducts: in vitro and in vivo applications
N. Mabon, K. Randerath (USA) 341–344

6c. Miscellaneous

Improvement in human health risk assessment utilizing site- and chemical-specific information: a case study
J.D. Pup, J. Kmiecik, S. Smith, F. Reitman (USA) 346–350
Butadiene inhalation accelerates arteriosclerotic plaque development in cockerels
A. Penn, C.A. Snyder (USA) 351–354

Session 7. FUTURE STUDIES AND SOCRATIC SESSION

Chair: M.G. Bird (Exxon Biomedical Sciences, Inc.)

Butadiene and isoprene: future studies and implications
H.M. Bolt (Germany) 356–360

Author index 361–362
Subject index 363–369
Volume contents 370–372